Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
Authors:
- Rakesh K SharmaRSRakesh K Sharma
- SharmaSHSharma
Open Access
- 1 November 2009
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 5, 965-972
Abstract
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting Rakesh K Sharma1, Hanumanth K Reddy1, Vibhuti N Singh2, Rohit Sharma1, Donald J Voelker1, Girish Bhatt11Medical Center of South Arkansas, El Dorado, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Bayfront Medical Center, St. Petersburg, University of South Florida, Tampa, FL, USA Patients undergoing coronary artery stenting receive an antiplatelet regimen to reduce the risk of antithrombotic complications. Current guidelines recommend the use of acetyl salicylic acid (aspirin) and clopidogrel as evidenced by large clinical trials. There has been a concern about variable responses of patients to aspirin and clopidogrel which may predispose them to subacute stent thrombosis or late stent thrombosis. Up to 25% of patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) were found to have hyporesponsiveness or resistance to clopidogrel which may predispose them to recurrent events. Dual antiplatelet regimen is a standard therapy in these patients and there is always a concern about variable responses to aspirin and clopidogrel predisposing them to acute coronary syndrome (ACS). Prevalence of this hyporesponsiveness or resistance may be due to noncompliance, genetic mutations, co-morbid situations and concomitant use of other drugs. This issue is of considerable importance in the era of coronary drug eluting stents when a long-term dual antiplatelet regimen is needed. This paper is a review for clinicians taking care of such patients with hyporesponsiveness or nonresponsiveness to dual antiplatelet regimen.Keywords: aspirin, clopidogrel, acute coronary syndrome, coronary artery stentingKeywords
This publication has 54 references indexed in Scilit:
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trialThe Lancet, 2008
- Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrelCanadian Medical Association Journal, 2006
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Platelet purinergic receptorsCurrent Opinion in Pharmacology, 2003
- Identification and functional characterization of new potentially defective alleles of human CYP2C19Pharmacogenetics, 2002
- How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and TransportClinical Chemistry and Laboratory Medicine (CCLM), 2000
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Aspirin as an Antiplatelet DrugNew England Journal of Medicine, 1994